DE3234203A1
(de)
*
|
1981-09-17 |
1983-07-07 |
Takeda Chemical Industries, Ltd., Osaka |
Macbecin-derivate und deren herstellung
|
US4578391A
(en)
*
|
1982-01-20 |
1986-03-25 |
Yamanouchi Pharmaceutical Co., Ltd. |
Oily compositions of antitumor drugs
|
JPS59102398A
(ja)
*
|
1982-12-03 |
1984-06-13 |
Takeda Chem Ind Ltd |
新規抗生物質およびその製造法
|
EP0664702A1
(en)
*
|
1992-10-14 |
1995-08-02 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Tumoricidal activity of benzoquinonoid ansamycins against prostate cancer and primitive neural malignancies
|
US5387584A
(en)
*
|
1993-04-07 |
1995-02-07 |
Pfizer Inc. |
Bicyclic ansamycins
|
JP2794342B2
(ja)
*
|
1993-06-29 |
1998-09-03 |
ファイザー・インク. |
抗癌遺伝子剤および抗癌剤としてのアンサマイシン誘導体
|
US5932566A
(en)
*
|
1994-06-16 |
1999-08-03 |
Pfizer Inc. |
Ansamycin derivatives as antioncogene and anticancer agents
|
CA2218523A1
(en)
*
|
1995-05-02 |
1996-11-07 |
William J. Welch |
Inducement of thermotolerance with benzoquinonoid ansamycins
|
CA2287387C
(en)
|
1997-05-14 |
2010-02-16 |
Sloan-Kettering Institute For Cancer Research |
Methods and compositions for destruction of selected proteins
|
US6852496B1
(en)
|
1997-08-12 |
2005-02-08 |
Oregon Health And Science University |
Methods of screening for agents that promote nerve cell growth
|
US6747055B1
(en)
|
1998-07-17 |
2004-06-08 |
The United States Of America As Represented By The Department Of Health And Human Services |
Water-soluble drugs and methods for their production
|
AU764603B2
(en)
|
1998-07-17 |
2003-08-21 |
United States Of America, Represented By The Secretary, Department Of Health And Human Services, The |
Water-soluble drugs and methods for their production
|
WO2000033858A1
(en)
*
|
1998-12-07 |
2000-06-15 |
Ecosmart Technologies, Inc. |
Cancer treatment composition and method using natural plant essential oils with signal transduction modulators
|
US6174875B1
(en)
*
|
1999-04-01 |
2001-01-16 |
University Of Pittsburgh |
Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
|
US7238682B1
(en)
|
1999-04-09 |
2007-07-03 |
Sloan-Kettering Institute For Cancer Research |
Methods and compositions for degradation and/or inhibition of HER-family tyrosine kinases
|
WO2000061578A1
(en)
*
|
1999-04-09 |
2000-10-19 |
Sloan-Kettering Institute For Cancer Research |
Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases
|
US6979574B1
(en)
*
|
1999-08-06 |
2005-12-27 |
Institut Fuer Diagnostik Forshung Gmbh |
Process for detecting binding reactions with use of the measurement of the relaxation of the double refraction of magnetic particles
|
US6887853B2
(en)
*
|
2000-06-29 |
2005-05-03 |
The Trustees Of Boston University |
Use of geldanamycin and related compounds for treatment of fibrogenic disorders
|
ATE526019T1
(de)
*
|
2000-07-28 |
2011-10-15 |
Sloan Kettering Inst Cancer |
Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen
|
AU2877202A
(en)
|
2000-11-02 |
2002-05-15 |
Sloan Kettering Inst Cancer |
Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors
|
AU2002252179A1
(en)
*
|
2001-03-01 |
2002-09-19 |
Conforma Therapeutics Corp. |
Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
|
MXPA03007856A
(es)
*
|
2001-03-30 |
2003-12-04 |
Us Health |
Derivado de geldanamicina y metodo de usarlo para tratar cancer.
|
JP2004529188A
(ja)
*
|
2001-05-23 |
2004-09-24 |
スローン − ケッタリング インスティチュート フォー キャンサー リサーチ |
上昇に関連した癌の治療法
|
US6872715B2
(en)
*
|
2001-08-06 |
2005-03-29 |
Kosan Biosciences, Inc. |
Benzoquinone ansamycins
|
WO2003013430A2
(en)
*
|
2001-08-06 |
2003-02-20 |
Kosan Biosciences, Inc. |
Benzoquinone ansamycins
|
US20090197852A9
(en)
*
|
2001-08-06 |
2009-08-06 |
Johnson Robert G Jr |
Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
|
JP2005504086A
(ja)
*
|
2001-09-24 |
2005-02-10 |
コンフォーマ セラピューティクス コーポレーション |
17−アリルアミノゲルダナマイシン(17−aag)および他のアンサマイシン類を製造する方法
|
EP1923061A1
(en)
|
2001-09-24 |
2008-05-21 |
Conforma Therapeutic Corporation |
Process for preparing 17-Allyl amino geldanamycin (17-AAG) and other ansamycins
|
AU2003217393B8
(en)
*
|
2002-02-08 |
2009-06-25 |
Conforma Therapeutics Corporation |
Ansamycins having improved pharmacological and biological properties
|
CA2481683A1
(en)
*
|
2002-04-10 |
2003-10-23 |
Conforma Therapeutics Corporation |
Ansamycin formulations and methods for producing and using same
|
US20060148776A1
(en)
*
|
2003-03-13 |
2006-07-06 |
Conforma Therapeutics Corporation |
Drug formulations having long and medium chain triglycerides
|
US20050026893A1
(en)
*
|
2003-05-30 |
2005-02-03 |
Kosan Biosciences, Inc. |
Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
|
US20050020556A1
(en)
*
|
2003-05-30 |
2005-01-27 |
Kosan Biosciences, Inc. |
Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
|
US20050054625A1
(en)
*
|
2003-05-30 |
2005-03-10 |
Kosan Biosciences, Inc. |
Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors
|
US7691838B2
(en)
*
|
2003-05-30 |
2010-04-06 |
Kosan Biosciences Incorporated |
Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
|
US20050020534A1
(en)
*
|
2003-05-30 |
2005-01-27 |
Kosan Biosciences, Inc. |
Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
|
US20050020557A1
(en)
*
|
2003-05-30 |
2005-01-27 |
Kosan Biosciences, Inc. |
Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
|
US20050054589A1
(en)
*
|
2003-05-30 |
2005-03-10 |
Kosan Biosciences, Inc. |
Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics
|
WO2005009345A2
(en)
*
|
2003-06-13 |
2005-02-03 |
Kosan Biosciences, Inc. |
2-desmethyl ansamycin compounds
|
WO2005056531A1
(en)
|
2003-11-12 |
2005-06-23 |
Kosan Biosciences, Inc. |
11-o-methylgeldanamycin compounds
|
US6875863B1
(en)
|
2003-11-12 |
2005-04-05 |
Kosan Biosciences, Inc. |
11-O-methylgeldanamycin compounds
|
US6887993B1
(en)
|
2003-11-12 |
2005-05-03 |
Kosan Biosciences, Inc. |
11-O-methylgeldanamycin compounds
|
US6855705B1
(en)
|
2003-11-12 |
2005-02-15 |
Kosan Biosciences, Inc. |
11-O-methylgeldanamycin compounds
|
US20060019941A1
(en)
*
|
2003-12-23 |
2006-01-26 |
Infinity Pharmaceuticals, Inc. |
Analogs of benzoquinone-containing ansamycins and methods of use thereof
|
ES2409351T3
(es)
*
|
2003-12-23 |
2013-06-26 |
Infinity Discovery, Inc. |
Análogos de ansamicinas que contienen benzoquinona para el tratamiento de cáncer
|
WO2005072766A2
(en)
*
|
2004-01-27 |
2005-08-11 |
Boys Town National Research Hospital |
Peptides that bind to hsp90 proteins
|
CA2559652C
(en)
*
|
2004-03-15 |
2017-02-14 |
Sunesis Pharmaceuticals, Inc. |
Methods of using sns-595 in treating cancer
|
US20050267087A1
(en)
*
|
2004-04-28 |
2005-12-01 |
Vassiliki Poulaki |
Inflammatory eye disease
|
US20050256097A1
(en)
*
|
2004-05-11 |
2005-11-17 |
Kosan Biosciences, Inc. |
Pharmaceutical solution formulations containing 17-AAG
|
US7259156B2
(en)
*
|
2004-05-20 |
2007-08-21 |
Kosan Biosciences Incorporated |
Geldanamycin compounds and method of use
|
US20080171687A1
(en)
*
|
2004-09-16 |
2008-07-17 |
Abraxis Bioscience, Inc. |
Compositions And Methods For The Preparation And Administration Of Poorly Water Soluble Drugs
|
US20060067953A1
(en)
*
|
2004-09-29 |
2006-03-30 |
Conforma Therapeutics Corporation |
Oral pharmaceutical formulations and methods for producing and using same
|
CN103143069B
(zh)
*
|
2005-02-18 |
2016-05-04 |
阿布拉西斯生物科学公司 |
用于整合入医疗装置的疏水性改善的药物
|
CA2602257A1
(en)
*
|
2005-03-30 |
2006-10-05 |
Conforma Therapeutics Corporation |
Alkynyl pyrrolopyrimidines and related analogs as hsp90-inhibitors
|
AU2006235105A1
(en)
*
|
2005-04-07 |
2006-10-19 |
Conforma Therapeutics Corporation |
Phospholipid-based pharmaceutical formulations and methods for producing and using same
|
JP2008535927A
(ja)
|
2005-04-12 |
2008-09-04 |
ウィスコンシン アルムニ リサーチ ファンデイション |
ポリマー及びパッセンジャー薬のミセル組成物
|
CN101175489A
(zh)
*
|
2005-04-29 |
2008-05-07 |
高山生物科学股份有限公司 |
用17-aag或17-ag或其前药治疗多发性骨髓瘤的方法
|
KR20080007642A
(ko)
*
|
2005-04-29 |
2008-01-22 |
코산 바이오사이언시즈, 인코포레이티드 |
프로테아좀 억제제와 함께 17-aag 또는 17-ag 또는 둘중 하나의 전구약물을 사용하여 다발성 골수종을 치료하는방법
|
US20080032719A1
(en)
*
|
2005-10-01 |
2008-02-07 |
Outland Research, Llc |
Centralized establishment-based tracking and messaging service
|
JP2008543941A
(ja)
*
|
2005-06-21 |
2008-12-04 |
インフィニティ・ディスカバリー・インコーポレイテッド |
アンサマイシン製剤およびその使用方法
|
US8580814B2
(en)
*
|
2006-04-03 |
2013-11-12 |
Sunesis Pharmaceuticals, Inc. |
Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
|
US20070105874A1
(en)
*
|
2005-09-23 |
2007-05-10 |
Conforma Therapeutics Corporation |
Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors
|
US7648976B2
(en)
*
|
2005-11-23 |
2010-01-19 |
Bristol-Myers Squibb Company |
17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
|
US20090042847A1
(en)
*
|
2005-11-23 |
2009-02-12 |
Kosan Biosciences Incorporated |
17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
|
WO2007064926A2
(en)
*
|
2005-12-01 |
2007-06-07 |
Conforma Therapeutics Corporation |
Compositions containing ansamycin
|
US20070167422A1
(en)
*
|
2006-01-18 |
2007-07-19 |
Yu Kwok S |
Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
|
US8658633B2
(en)
*
|
2006-02-16 |
2014-02-25 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for treating conditions of the eye
|
BRPI0713637A2
(pt)
|
2006-06-12 |
2012-10-23 |
Sunesis Pharmaceuticals Inc |
composição, composto, e , método para o tratamento de cáncer
|
US20080063642A1
(en)
*
|
2006-08-02 |
2008-03-13 |
Adelman Daniel C |
Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disorders
|
PE20081506A1
(es)
*
|
2006-12-12 |
2008-12-09 |
Infinity Discovery Inc |
Formulaciones de ansamicina
|
EP2121957A4
(en)
*
|
2007-01-26 |
2010-11-10 |
Kosan Biosciences Inc |
MACROLACTAMES OBTAINED BY MODIFIED BIOSYNTHESIS
|
US8303960B2
(en)
*
|
2007-02-27 |
2012-11-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Radiolabeled affibody molecules
|
JP5454943B2
(ja)
*
|
2007-04-12 |
2014-03-26 |
ジョイアント ファーマスーティカルズ、インク. |
抗癌剤として有用なsmac模倣二量体及び三量体
|
BRPI0810835A2
(pt)
*
|
2007-04-12 |
2015-06-16 |
Infinity Discovery Inc |
Formulações de hidroquinona ansamicina
|
US20100203114A1
(en)
*
|
2007-07-09 |
2010-08-12 |
Warf - Wisconsin Alumni Research Foundation |
Micelle encapsulation of therapeutic agents
|
EP2190291B1
(en)
*
|
2007-08-23 |
2015-10-14 |
The Regents of The University of Colorado, A Body Corporate |
Hsp90 inhibitors with modified toxicity
|
EP2200653A2
(en)
|
2007-09-10 |
2010-06-30 |
University of Massachusetts |
Mitochondria-targeted anti-tumour agents
|
EP3141250A1
(en)
*
|
2007-10-22 |
2017-03-15 |
Sunesis Pharmaceuticals, Inc. |
Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy
|
WO2009086170A1
(en)
*
|
2007-12-21 |
2009-07-09 |
Joyant Pharmaceuticals, Inc. |
Diazonamide analogs with improved solubility
|
CN101220068B
(zh)
*
|
2008-01-18 |
2012-06-13 |
中国医学科学院医药生物技术研究所 |
一组格尔德霉素衍生物及其制备方法
|
US20090258869A1
(en)
*
|
2008-02-08 |
2009-10-15 |
The Regents Of The University Of California |
Methods and compounds for treatment or prevention of substance-related disorders
|
JP5123429B2
(ja)
*
|
2008-04-29 |
2013-01-23 |
ジョイアント ファーマスーティカルズ、インク. |
インドリン抗癌剤
|
US8153619B2
(en)
*
|
2008-05-22 |
2012-04-10 |
Joyant Pharmaceuticals, Inc. |
Diazonamide analogs
|
EP2348845A4
(en)
*
|
2008-10-15 |
2013-01-23 |
Infinity Pharmaceuticals Inc |
ANSAMYCIN HYDROQUINONE COMPOSITIONS
|
DE102008060549A1
(de)
|
2008-12-04 |
2010-06-10 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
|
WO2011038278A2
(en)
|
2009-09-25 |
2011-03-31 |
Wisconsin Alumni Research Foundation |
Micelle encapsulation of therapeutic agents
|
EP2471918A4
(en)
|
2009-09-29 |
2013-06-05 |
Takeda Pharmaceutical |
SCREENING PROCESS
|
WO2011059763A2
(en)
|
2009-10-28 |
2011-05-19 |
Joyant Pharmaceuticals, Inc. |
Dimeric smac mimetics
|
CN102603635B
(zh)
*
|
2011-01-21 |
2016-08-03 |
杭州华东医药集团生物工程研究所有限公司 |
格尔德霉素衍生物及其制备方法和用途
|
ES2652444T3
(es)
|
2011-04-22 |
2018-02-02 |
Joyant Pharmaceuticals, Inc. |
Análogos de diazonamida
|
WO2012151544A1
(en)
|
2011-05-05 |
2012-11-08 |
Wisconsin Alumni Research Foundation |
Micelles for the solubilization of gossypol
|
WO2013053833A1
(en)
|
2011-10-14 |
2013-04-18 |
Novartis Ag |
2 - carboxamide cycloamino urea derivatives in combination with hsp90 inhibitors for the treatment of proliferative diseases
|
WO2013074695A1
(en)
|
2011-11-14 |
2013-05-23 |
The Regents Of The University Of Colorado, A Body Corporate |
Hsp90 inhibitors with modified toxicity
|
JP6158833B2
(ja)
|
2012-01-09 |
2017-07-05 |
アローヘッド ファーマシューティカルズ インコーポレイテッド |
ベータ−カテニン関連疾患を処置するための有機組成物
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
EP3795694A3
(en)
|
2012-10-02 |
2021-06-23 |
The General Hospital Corporation d/b/a Massachusetts General Hospital |
Methods relating to dna-sensing pathway related conditions
|
RU2015121424A
(ru)
|
2012-11-07 |
2016-12-27 |
Новартис Аг |
Комбинированная терапия
|
SI2958907T1
(en)
|
2013-02-19 |
2018-05-31 |
Novartis Ag |
Benzothiophene derivatives and their compositions as selective estrogen receptor antagonists
|
CN103360312B
(zh)
*
|
2013-07-22 |
2015-06-03 |
山东大学 |
一组格尔德霉素衍生物及其应用
|
KR20160104612A
(ko)
|
2013-07-26 |
2016-09-05 |
업데이트 파마 인코포레이트 |
비산트렌의 치료 효과 개선용 조성물
|
WO2015092634A1
(en)
|
2013-12-16 |
2015-06-25 |
Novartis Ag |
1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
|
CN105899491B
(zh)
|
2014-01-17 |
2019-04-02 |
诺华股份有限公司 |
用于抑制shp2活性的1-哒嗪-/三嗪-3-基-哌(-嗪)/啶/吡咯烷衍生物及其组合物
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
US9815813B2
(en)
|
2014-01-17 |
2017-11-14 |
Novartis Ag |
1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2
|
AU2016238436A1
(en)
|
2015-03-25 |
2017-08-17 |
Novartis Ag |
Formylated N-heterocyclic derivatives as FGFR4 inhibitors
|
EP3307264A1
(en)
|
2015-06-12 |
2018-04-18 |
Wisconsin Alumni Research Foundation |
Multi-drug combinations that act as potent radiosensitizers
|
WO2016203404A1
(en)
|
2015-06-19 |
2016-12-22 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of shp2
|
JP6878316B2
(ja)
|
2015-06-19 |
2021-05-26 |
ノバルティス アーゲー |
Shp2の活性を阻害するための化合物および組成物
|
WO2016203406A1
(en)
|
2015-06-19 |
2016-12-22 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of shp2
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
US10577362B2
(en)
|
2016-05-04 |
2020-03-03 |
Genoscience Pharma |
Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases
|
US10934285B2
(en)
|
2016-06-14 |
2021-03-02 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of SHP2
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
CN111201223B
(zh)
|
2017-09-11 |
2024-07-09 |
克鲁松制药公司 |
SHP2的八氢环戊二烯并[c]吡咯别构抑制剂
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
WO2020021322A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) Srl |
Stable, concentrated radionuclide complex solutions
|
MX2021003158A
(es)
|
2018-09-18 |
2021-07-16 |
Nikang Therapeutics Inc |
Derivados de anillo tricíclico condensado como inhibidores de la fosfatasa de homología a src 2.
|
CN117122707A
(zh)
|
2018-09-25 |
2023-11-28 |
意大利国际先进加速器应用有限公司 |
联合疗法
|
CN113382986A
(zh)
|
2018-09-25 |
2021-09-10 |
黑钻治疗公司 |
酪氨酸激酶抑制剂组合物、其制备方法和使用方法
|
US20220041613A1
(en)
|
2018-09-25 |
2022-02-10 |
Black Diamond Therapeutics, Inc. |
Tyrosine kinase inhibitor compositions, methods of making and methods of use
|
KR20210068473A
(ko)
|
2018-09-29 |
2021-06-09 |
노파르티스 아게 |
Shp2 활성 억제용 화합물의 제조 방법
|
BR112021011874A2
(pt)
|
2018-12-20 |
2021-09-08 |
Novartis Ag |
Regime de dosagem e combinação farmacêutica compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona
|
CN113490528A
(zh)
|
2019-02-15 |
2021-10-08 |
诺华股份有限公司 |
3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
CN113329792B
(zh)
|
2019-02-15 |
2024-06-28 |
诺华股份有限公司 |
取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
BR112022002518A2
(pt)
|
2019-08-15 |
2022-07-19 |
Black Diamond Therapeutics Inc |
Compostos de alquinila quinazolina
|
CA3165399A1
(en)
|
2019-12-20 |
2021-06-24 |
Novartis Ag |
Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
|
WO2021195206A1
(en)
|
2020-03-24 |
2021-09-30 |
Black Diamond Therapeutics, Inc. |
Polymorphic forms and related uses
|
CA3182346A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
EP4204021A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
WO2022043556A1
(en)
|
2020-08-31 |
2022-03-03 |
Novartis Ag |
Stable radiopharmaceutical composition
|
US20230338587A1
(en)
|
2020-08-31 |
2023-10-26 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
IL303661A
(en)
|
2020-12-22 |
2023-08-01 |
Nikang Therapeutics Inc |
COMPOUNDS FOR BREAKING CYCLIN-DEPENDENT KINASE 2 THROUGH THE UBIQUITIN PROTEOSOME PATHWAY
|
AU2022207648A1
(en)
|
2021-01-13 |
2023-07-27 |
Monte Rosa Therapeutics Ag |
Isoindolinone compounds
|
WO2022170052A1
(en)
|
2021-02-05 |
2022-08-11 |
Black Diamond Therapeutics, Inc. |
Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
WO2022219412A1
(en)
|
2021-04-14 |
2022-10-20 |
Monte Rosa Therapeutics Ag |
Isoindolinone amide compounds useful to treat diseases associated with gspt1
|
WO2022219407A1
(en)
|
2021-04-14 |
2022-10-20 |
Monte Rosa Therapeutics Ag |
Isoindolinone compounds
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
WO2023284730A1
(en)
|
2021-07-14 |
2023-01-19 |
Nikang Therapeutics, Inc. |
Alkylidene derivatives as kras inhibitors
|
WO2023192801A1
(en)
|
2022-03-28 |
2023-10-05 |
Nikang Therapeutics, Inc. |
Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
WO2023240024A1
(en)
|
2022-06-08 |
2023-12-14 |
Nikang Therapeutics, Inc. |
Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors
|
WO2024102849A1
(en)
|
2022-11-11 |
2024-05-16 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
|